• 中文
    • 登錄
    • 聯系我們
    ×
    目錄產品 » 抗體產品 » 一抗 » 免疫檢查點抗體和蛋白 » Anti-Atezolizumab Antibody (6B12) [Biotin], mAb, Mouse
    Anti-Atezolizumab Antibody (6B12) [Biotin], MAb, Mouse

    Anti-Atezolizumab Antibody (6B12), mAb, Mouse (GenScript, A01950-40) binds with Atezolizumab. While the antibody does not recognize the human IgG Fc fragment (data not shown).
    Coating antigen: Atezolizumab, 1 μg/ml.
    Anti-Atezolizumab antibody (GenScript, A01950-40) dilution start from 1,000 ng/ml.
    EC??= 8.464 ng/ml.

    Anti-Atezolizumab Antibody (6B12) [Biotin], MAb, Mouse

    Standard curve of Atezolizumab Sandwich ELISA. The Atezolizumab Sandwich ELISA assay is developed by using Anti-Atezolizumab Antibody (10G9), mAb, Mouse (GenScript, A01948-40) and Anti-Atezolizumab Antibody (6B12) [Biotin], mAb, Mouse (GenScript, A01950-40) as capture and detection antibody, respectively.
    The sensitivity of detecting Rituximab is about 97 pg/ml.

    Anti-Atezolizumab Antibody (6B12) [Biotin], mAb, Mouse

    The product is specific for Atezolizumab. The antibody is recommended as a detection antibody in a pharmacokinetic (PK) bridging assay with capture antibody GenScript, A01948-40, Anti-Atezolizumab Antibody (10G9), mAb, Mouse.
    A01950
    ¥990

    聯系我們
    Specificity The product is specific for Atezolizumab. The antibody is recommended as a detection antibody in a pharmacokinetic (PK) bridging assay with capture antibody GenScript, A01948-40, Anti-Atezolizumab Antibody (10G9), mAb, Mouse.
    Host Species Mouse
    Immunogen Atezolizumab
    Conjugate Biotin

    Working concentrations for specific applications should be determined by the investigators. The appropriate concentration may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
    Application Recommended Usage
    ELISA 0.01-1 μg/ml

    Form Lyophilized
    Storage Buffer lyophilized with PBS, pH 7.4, contains 1% BSA and 0.02% sodium azide.
    Reconstitution Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL.
    Storage Instructions The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
    Purification Protein A affinity column
    Isotype Mouse IgG1,κ
    Clonality Monoclonal
    Clone ID 6B12
    Note GenScript can customize this product per customer's request including product size, buffer components, etc.

    • Anti-Atezolizumab Antibody (6B12) [Biotin], MAb, Mouse
    • Anti-Atezolizumab Antibody (6B12) [Biotin], MAb, Mouse

      Anti-Atezolizumab Antibody (6B12), mAb, Mouse (GenScript, A01950-40) binds with Atezolizumab. While the antibody does not recognize the human IgG Fc fragment (data not shown).
      Coating antigen: Atezolizumab, 1 μg/ml.
      Anti-Atezolizumab antibody (GenScript, A01950-40) dilution start from 1,000 ng/ml.
      EC??= 8.464 ng/ml.

    • Anti-Atezolizumab Antibody (6B12) [Biotin], MAb, Mouse
    • Anti-Atezolizumab Antibody (6B12) [Biotin], MAb, Mouse

      Standard curve of Atezolizumab Sandwich ELISA. The Atezolizumab Sandwich ELISA assay is developed by using Anti-Atezolizumab Antibody (10G9), mAb, Mouse (GenScript, A01948-40) and Anti-Atezolizumab Antibody (6B12) [Biotin], mAb, Mouse (GenScript, A01950-40) as capture and detection antibody, respectively.
      The sensitivity of detecting Rituximab is about 97 pg/ml.


    Target Background Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 receptors (B7-1Rs). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer. Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as "immune checkpoint inhibition."
    Synonyms Mouse monoclonal to Tecentriq

    For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


    国产小受呻吟cv视频在线观看